Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LT0U
|
|||
| Former ID |
DIB007067
|
|||
| Drug Name |
ORG-25935
|
|||
| Synonyms |
Cis-N-(6-Methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-N-methylglycine hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H25NO3
|
|||
| Canonical SMILES |
CN(CC1CCC2=C(C1C3=CC=CC=C3)C=CC(=C2)OC)CC(=O)O
|
|||
| InChI |
1S/C21H25NO3/c1-22(14-20(23)24)13-17-9-8-16-12-18(25-2)10-11-19(16)21(17)15-6-4-3-5-7-15/h3-7,10-12,17,21H,8-9,13-14H2,1-2H3,(H,23,24)/t17-,21+/m1/s1
|
|||
| InChIKey |
UEBBYLJZCHTLEG-UTKZUKDTSA-N
|
|||
| CAS Number |
CAS 1147011-84-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycine transporter GlyT-1 (SLC6A9) | Target Info | Inhibitor | [2], [3] |
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | NRF2 pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00725725) Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705AM3)(TERMINATED). U.S. National Institutes of Health. | |||
| REF 2 | The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014 Apr;34(2):190-8. | |||
| REF 3 | Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.